TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Hutchmed (China) Limited
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

The SACHI Phase III trial demonstrated that the combination of savolitinib (ORPATHYS®) and osimertinib (TAGRISSO®) significantly improved progression-free survival (8.2 vs 4.5 months) compared to chemotherapy in patients with EGFR-mutated NSCLC with MET amplification after EGFR-TKI progression. The combination was approved in China in June 2025 and results were published in The Lancet.

Insights
COIN   positive

Committed to increasing economic freedom and being a trusted, compliant cryptocurrency exchange in Singapore


HCM   positive

Positive Phase III trial results showing significant clinical benefit (PFS improvement of 82% over chemotherapy), regulatory approval in China, and publication in prestigious journal (The Lancet). Strong efficacy data supports commercial potential and validates the combination strategy.